150 related articles for article (PubMed ID: 32782621)
1. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the
Yan Z; Gu YY; Hu XD; Zhao Q; Kang HL; Wang M; Duan W; Guan Y
Oncol Lett; 2020 Sep; 20(3):3035-3045. PubMed ID: 32782621
[TBL] [Abstract][Full Text] [Related]
2. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
3. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
4. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
5. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
6. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the
Song ZZ; Zhao LF; Zuo J; Fan ZS; Wang L; Wang YD
Onco Targets Ther; 2020; 13():603-613. PubMed ID: 32021302
[TBL] [Abstract][Full Text] [Related]
7. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
Bai M; Li ZG; Ba Y
Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
[TBL] [Abstract][Full Text] [Related]
8. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
9. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
10. Association Between
Hu W; Li B; Geng N; He X; Ge H; Wang P; Ding C
Int J Gen Med; 2021; 14():2703-2714. PubMed ID: 34188525
[TBL] [Abstract][Full Text] [Related]
11. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
13. [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Du YB; Zhang TF; Cui K; Jin SL; Xi Y; Ma W
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2569-2573. PubMed ID: 30220141
[No Abstract] [Full Text] [Related]
14. Correlation between VEGFR2 rs2071559 polymorphism and glioma risk among Chinese population.
Xu GZ; Liu Y; Zhang Y; Yu J; Diao B
Int J Clin Exp Med; 2015; 8(9):16724-8. PubMed ID: 26629211
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis].
Chen WC; Wu G; Zhang W; Zhu YZ; Zhou Y; Zhang H; Xia XB; Sun PC
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3420-3425. PubMed ID: 30440137
[No Abstract] [Full Text] [Related]
16. Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study.
Meng L; Cao J; Kang L; Xu G; Yuan DW; Li K; Zhu K
Pharmgenomics Pers Med; 2023; 16():1027-1039. PubMed ID: 38046381
[TBL] [Abstract][Full Text] [Related]
17. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apatinib for elderly patients with previously treated extensive-stage colorectal cancer patients and the prognostic significance of common adverse reactions.
Yu Y; Li Y; Xu C; Zhang W
Indian J Cancer; 2023 Feb; ():. PubMed ID: 36861718
[TBL] [Abstract][Full Text] [Related]
19. Implication of PD‑L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD‑1 blockades: A retrospective exploratory study.
Gong Q; Qie HL; Dong SY; Jiang HT
Oncol Lett; 2024 Apr; 27(4):144. PubMed ID: 38385107
[TBL] [Abstract][Full Text] [Related]
20. Influence of
Zhao M; Zhang J; Chen S; Wang Y; Tian Q
Cancer Manag Res; 2020; 12():6755-6766. PubMed ID: 32801904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]